MT-2 (Melanotan II): Melanocortin Receptor Research
Melanotan II (MT-2, MT-II) is a synthetic cyclic heptapeptide derived from the endogenous hormone alpha-melanocyte-stimulating hormone (alpha-MSH). It is one of the best-characterised tools in melanocortin receptor research, largely because its design addressed two problems that limit the native hormone in the laboratory: rapid enzymatic degradation and a short duration of action. This article summarises the compound's chemistry, its receptor pharmacology and the published literature, and then covers practical points on handling it in a research setting.
Background: the melanocortin system
The melanocortins are a family of peptides, including alpha-, beta- and gamma-MSH and ACTH, all cleaved from the precursor proopiomelanocortin (POMC). They signal through five G protein-coupled receptors, MC1R to MC5R, which couple primarily to adenylyl cyclase and cyclic AMP. The receptors have distinct tissue distributions: MC1R is expressed prominently on melanocytes, MC2R is the ACTH receptor of the adrenal cortex, MC3R and MC4R are expressed in the central nervous system, and MC5R is found in a range of peripheral exocrine tissues.
Native alpha-MSH is a 13-residue peptide that is rapidly degraded in biological matrices, which makes it awkward to use in experiments that need sustained receptor activation. Medicinal chemists therefore set out to build analogues that were more potent, more stable and, ideally, more selective. Melanotan II emerged from that programme.
Discovery and structure
Melanotan II was designed by Victor Hruby, Mac Hadley and colleagues at the University of Arizona. Al-Obeidi and co-workers described the design strategy in the Journal of the American Chemical Society (1989; 111:3413-3416), using quenched molecular dynamics and molecular mechanics, together with earlier structure-activity data, to arrive first at a potent linear fragment and then a cyclic lactam analogue. In classical bioassays the cyclic compound was reported to be roughly 90 times more potent than alpha-MSH in the lizard skin assay and about 100 times more potent in a mammalian melanoma tyrosinase assay, with prolonged activity.
The structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Three features explain much of its behaviour. First, a lactam bridge between the aspartic acid and lysine side chains constrains the peptide into a cyclic conformation that stabilises the bioactive turn. Second, norleucine replaces the oxidation-prone methionine found in the native sequence. Third, a D-phenylalanine residue replaces L-phenylalanine, which increases potency and resistance to proteolysis. The core His-Phe-Arg-Trp motif is the pharmacophore shared across the melanocortin family.
The molecular formula is C50H69N15O9, the molecular weight is approximately 1,024 Da, and the CAS registry number is 121062-08-6.
Receptor pharmacology
Melanotan II is described as a non-selective melanocortin receptor agonist, with activity reported at MC1R, MC3R, MC4R and MC5R. That lack of selectivity is central to how it is used and interpreted. Research groups use it as a broad agonist to probe what melanocortin signalling does as a whole, and then use more selective ligands or receptor-deficient models to assign individual effects to individual receptor subtypes.
The pharmacology is usually discussed in two broad domains. In pigmentation research, the relevant target is MC1R on melanocytes, where receptor activation raises intracellular cAMP and shifts melanin synthesis. In neuroscience research, the relevant targets are MC3R and MC4R in hypothalamic and limbic circuits, which have been studied in animal models in connection with energy balance, feeding behaviour and sexual behaviour. Hadley and Dorr reviewed the programme in Peptides (2006; 27:921-930), noting that MT-I, a linear analogue, and MT-II, the cyclic truncated analogue, were taken forward for different research questions.
Melanotan II is also the structural parent of bremelanotide (PT-141), a closely related analogue developed separately that is itself a melanocortin agonist. Comparisons between the two have been useful for understanding how small structural changes alter receptor selectivity and pharmacokinetics.
What the published literature reports
The earliest human-subject work on the compound was a small pilot study by Dorr and colleagues (Life Sciences, 1996; 58:1777-1784). Three healthy male volunteers took part in a single-blind, placebo-controlled escalation. The authors reported increased skin pigmentation in two of the three subjects, together with nausea, somnolence and fatigue at higher exposures, and observed stretching and yawning followed by spontaneous penile erections. These observations pointed to both peripheral (MC1R-linked) and central (MC3R/MC4R-linked) activity.
A follow-up double-blind, placebo-controlled crossover study by Wessells and colleagues (Urology, 2000; 56:641-646) examined the erectile response in ten men with erectile dysfunction and organic risk factors. The authors reported erections following 12 of 19 active administrations compared with 1 of 21 placebo administrations, along with increased reported sexual desire, and noted nausea and stretching or yawning as common accompanying observations. They concluded that the response was not limited to psychogenic causes and that centrally acting melanocortin agents merited further study.
These studies are historical, small and exploratory, and they are cited here as part of the scientific record on the compound rather than as evidence of any benefit. Melanotan II is not an approved medicine.
The literature also contains safety-relevant observations. Case reports in dermatology journals, for example Cardones and Grichnik (Archives of Dermatology, 2009) and Cousen and colleagues (British Journal of Dermatology, 2009), described changes in pigmented lesions in individuals who had obtained unregulated melanocortin products. Case reports cannot establish causation, but they are part of why the pigmentary effects of non-selective MC1R agonism remain a topic of careful discussion among researchers.
Relationship to other melanocortin analogues
Placing Melanotan II alongside its relatives clarifies why it remains in use. Melanotan I (afamelanotide, also known as NDP-alpha-MSH) is a linear 13-residue analogue that retains the full alpha-MSH backbone with norleucine and D-phenylalanine substitutions. It was developed principally for pigmentation research, whereas the shorter cyclic Melanotan II was taken forward for broader work that included central melanocortin receptors. Setmelanotide, a later cyclic peptide, was engineered with a bias toward MC4R, illustrating the field's trajectory from broad agonists toward receptor-selective ligands. In practical terms, a laboratory choosing between these tools is choosing between breadth and selectivity: a broad agonist is useful for establishing whether the melanocortin system is involved at all, while a selective ligand is useful for deciding which receptor is responsible.
The cyclisation strategy used for Melanotan II has also been influential beyond this single compound. Lactam-bridged scaffolds of this type became a template for studying how conformational restriction influences receptor recognition, and structure-activity series built on the Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 framework continue to appear in the medicinal-chemistry literature. Those series typically vary the ring size, the stereochemistry of the aromatic residue or the side-chain lengths in order to map which features drive affinity and which drive receptor-subtype discrimination.
Experimental design considerations
Because Melanotan II activates several receptor subtypes at once, interpreting an in vitro or animal result depends on controlling for that breadth. Common approaches include comparing responses in cell lines expressing a single melanocortin receptor, using receptor antagonists or inverse agonists such as agouti-related protein fragments, and using knockout or receptor-deficient animal models. Concentration-response curves and cAMP accumulation assays are the usual in vitro readouts, while behavioural endpoints in rodents require careful controls for nausea-related effects, a recognised confound in feeding studies.
Analytical verification matters as much as experimental design. Peptide identity and purity should be confirmed by both HPLC and mass spectrometry, because a correct mass confirms the sequence while a chromatographic trace estimates purity. Batch documentation allows a laboratory to link its data to a specific analytical record, and the article on HPLC and mass spectrometry explains how to read those figures.
Handling and storage
Lyophilised Melanotan II is generally supplied as a white powder. Suppliers of research-grade material typically recommend storing the dry powder desiccated below -18 °C for long-term retention, and note that it tolerates short periods at ambient temperature during shipping. Once reconstituted, solutions are typically held at 2-8 °C for a short window, with repeated freeze-thaw cycles avoided because they promote aggregation and degradation; aliquoting into single-use volumes before freezing is standard practice. The tryptophan residue makes the peptide somewhat sensitive to light and oxidation, so protection from prolonged light exposure is sensible. General guidance is covered in the guide to peptide storage and handling.
Researchers can review batch documentation on the Lab Results page and the specifications for MT-2 (Melanotan II) before planning an experiment.
Summary
Melanotan II is a cyclic, lactam-bridged alpha-MSH analogue whose enhanced potency and stability made it a durable reference agonist in melanocortin research. Its broad activity across MC1R, MC3R, MC4R and MC5R is both its value as a general probe and its main interpretive challenge. The published record comprises foundational medicinal-chemistry work from the late 1980s, small exploratory studies in 1996 and 2000, and later dermatology case reports, and it continues to inform how newer, more selective melanocortin ligands are designed and evaluated.
Research use only. Not a medicine, supplement or therapeutic good. Not for human or veterinary consumption.